Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesThiazolidinediones and vascular damage
Current Opinion in Endocrinology and Diabetes, 03/05/07
Goldberg, Ronald B, - Will use of these drugs prevent cardiovascular disease?
>Summary: The purpose of this review was to investigate the possibility of thiazolidinedione agents having vasculoprotective effects and if so whether these are associated with the prevention of cardiovascular disease.
Outcomes: The weight of the experimental, subclinical and clinical assessments of the effects of these agents supports the contention that they are vasculoprotective. In the final analysis their use in clinical practice to prevent cardiovascular disease will mostly depend on whether clinical trials consistently demonstrate that they reduced cardiovascular events
| Previous Article | Next Article |
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review
Annals of Rheumatic Diseases, 06/09/09
Denosumab update
Current Opinion in Rheumatology, 06/11/09
Dapsone 5 Gel: A Review of its Efficacy and Safety in the Treatment of Acne Vulgaris
American Journal of Clinical Dermatology, 06/09/09
Today in Endocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet, 06/23/09
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
Vascular Health and Risk Management, 05/11/09
A randomized trial of therapies for type 2 diabetes and coronary artery disease
New England Journal of Medicine, 06/10/09
Today in Vascular Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Management of hypertension in acute stroke
Expert Review of Cardiovascular Therapy , 06/12/09
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
Vascular Health and Risk Management, 05/11/09
Sponsor
Article Search
Sponsor